Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
31 juil. 2024 09h00 HE
|
Vaccinex, Inc.
Positive data for SIGNAL-AD trial of Pepinemab in Alzheimer’s Disease affirm expectation of a novel mechanism to delay progression of Alzheimer’s disease
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
17 juil. 2024 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
04 déc. 2023 08h00 HE
|
Vaccinex, Inc.
Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ...
Konica Minolta Raises $125,000 for Alzheimer’s Research
24 oct. 2023 10h37 HE
|
Konica Minolta Business Solutions U.S.A., Inc.
Ramsey, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced the final fundraising results through its participation in the...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
01 juin 2023 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
25 avr. 2023 08h00 HE
|
Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....
Vaccinex Announces $3.8 Million Private Placement
28 nov. 2022 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Konica Minolta Raises $97,000 for Alzheimer’s Research
06 oct. 2022 15h32 HE
|
Konica Minolta Business Solutions U.S.A., Inc.
Ramsey, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced the final fundraising results through its participation in the...
Help Dixie Belle Paint Raise Up to $15,000 for the Fight Against Alzheimer's.
06 sept. 2022 15h00 HE
|
Dixie Belle Paint
PORT RICHEY, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Help Dixie Belle Paint raise up to $15,000 for the fight against Alzheimer's. Visit Dixie Belle on Facebook at Dixie Belle Paint Company and...
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
29 juil. 2022 07h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...